Nuvation Bio earnings beat by $0.02, revenue was in line with estimates

Nuvation Bio earnings beat by $0.02, revenue was in line with estimates

Nuvation Bio (NYSE: NUVB) reported first-quarter EPS of $-0.100, $0.02

better than the analyst estimate of $-0.121. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.

Nuvation Bio's stock price closed at $1.660. It is down -6.210% in the last 3 months and down -69.260% in the last 12 months.

Nuvation Bio saw 1 positive EPS revision and 0 negative EPS revisions in the last 90 days.

See Nuvation Bio's stock price’s past reactions to earnings here.

According to InvestingPro, Nuvation Bio's Financial Health score is "performance".